Navigation Links
Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab
Date:8/14/2008

First T cell engaging antibody (BiTE) showing clinical benefit in cancer patients; Blinatumomab enables patients own T cells to recognize and attack

cancer cells

BETHESDA, Md., Aug. 14 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced publication of a Phase 1 clinical study(1) on its BiTE(R) antibody blinatumomab (MT103/MEDI-538) in this week's issue of Science. The article is available at http://www.sciencemag.org. Blinatumomab is being co-developed with MedImmune.

Blinatumomab is a novel antibody therapy that activates a patient's T cells to seek out and destroy cancer cells. The phase 1 study demonstrated tumor regression, and in some cases, complete remission, in non-Hodgkin's lymphoma patients who relapsed after previous treatments and were considered to have incurable disease. Most of the remissions are reported to continue, with the longest remission ongoing for more than one year. Results from this ongoing Phase 1 clinical trial with the CD19-specific BiTE antibody blinatumomab show that all seven patients treated to date at 0.06 mg/m2 per day achieved complete or partial responses. The safety profile observed in this study supports continued blinatumomab development.

"These results represent significant progress of a T cell engaging antibody for treatment of lymphoma patients as single agent therapy. We observed tumor regression in patients at serum levels of blinatumomab, which are approximately five orders of magnitude lower than serum levels needed by conventional m
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Clinical Trials Bootcamp Announces Inaugural Meeting
2. Aon eSolutions Launches Clinical Trials Module
3. Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders
4. NewCardio Announces Positive Results From Third Clinical Validation Study
5. Isis Initiates Clinical Trial of CRP Drug
6. U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)
7. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
8. Journal of the American Dental Association Publishes Key Clinical Data for the Use of OraVerse(TM) a Local Anesthetic Reversal Agent
9. Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma
10. M. D. Anderson to Initiate Clinical Validation Study on Rosetta Genomics MicroRNA-based Diagnostic Assay Identifying the Origin of Cancer Metastases
11. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... Alimera Sciences, Inc. (NASDAQ: ... in the research, development and commercialization of prescription ... fourth quarter and year ended December 31, 2014. ... year for Alimera Sciences, most notably having received ... the treatment of diabetic macular edema," said Dan ...
(Date:3/4/2015)... March 4, 2015 Acsis Inc., the market ... solutions, announced it will be hosting a free webinar ... event, "How to Boost Manufacturing Efficiency and Optimize Supply ... at 2:00 PM EDT.  Presenters ... John Gordon , Chief Information Officer for Roosevelt ...
(Date:3/4/2015)... , March 4, 2015   Mayo Clinic ... to develop the next generation of wearable biosensors designed ... hoping that this technology will be game-changer. These patch ... says James Levine, M.D., Ph.D. , a Mayo ... accurate, inexpensive, and can be integrated into the care ...
Breaking Medicine Technology:Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 2Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 3Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 4Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 5Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 6Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 7Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 8Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 9Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 10Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 11Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 12Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 13Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 14Mayo Clinic and Gentag, Inc. Announce Agreement To Develop Wireless Sensors for Treatment of Obesity and Diabetes 2Mayo Clinic and Gentag, Inc. Announce Agreement To Develop Wireless Sensors for Treatment of Obesity and Diabetes 3
... Feb. 8, 2012   Resource Anesthesia , an anesthesia ... several new locations to its management portfolio. ... announced today that the company has added the following ... Specialty Hospital of Washington -- Hadley, 4601 Martin Luther ...
... MLAB ) today reported a 21 percent increase in revenue and ... quarter ended December 31, 2011. Highlights: ... ,000 Quarterly revenues increased 21% year over year to ... in the fiscal third quarter Quarterly non-GAAP diluted earnings ...
Cached Medicine Technology:Resource Anesthesia Adds Locations Under Management, Announces Addition of HealthStream LearningCenter® 2Mesa Labs Reports 58 Percent Increase in Third Quarter Net Income 2Mesa Labs Reports 58 Percent Increase in Third Quarter Net Income 3Mesa Labs Reports 58 Percent Increase in Third Quarter Net Income 4Mesa Labs Reports 58 Percent Increase in Third Quarter Net Income 5
(Date:3/4/2015)... When people talk about venues being the place ... numerous genres, the Houston Rodeo will be a ... the annual livestock show and rodeo, one popular band will ... being held at the event. The 2015 show will feature ... try and get the festival its largest attendance ever. , ...
(Date:3/4/2015)... The federal litigation established for Lipitor ... caused patients to develop Type 2 diabetes continues to ... South Carolina. According to court documents, the proceeding’s next ... at 10:00 a.m. In advance of the Conference, the ... report to the Court by March 19, 2015. (In ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 FDA’s New ... , **FDAnews Webinar**, March 24, 2015 — 1:30 p.m. ... investigators generally know within four hours of an inspection ... manufacturer is on their “good” list, they’ll merely ask ... a manufacturer is on the “bad” list, the manufacturer ...
(Date:3/4/2015)... VIENNA, Austria (PRWEB) March 04, 2015 ... to reduce subjectivity in density assessment and help ... focus of numerous abstracts accepted for presentation at ... 3-8, 2015. Ten abstracts - eight posters ... of Volpara Solutions’ automated breast density and quantitative ...
(Date:3/4/2015)... 04, 2015 With the growing influence of ... of our teens and young adults, combined with the increasingly ... confusing to try to keep up with what kids are ... trend is replaced on a daily basis. , The same ... the slang that is used to discreetly talk about them, ...
Breaking Medicine News(10 mins):Health News:Cheap Houston Rodeo Tickets: Ticket Down Slashes Houston Rodeo Tickets for John Legend, Pitbull, Alan Jackson, Tim McGraw, Zac Brown Band, Fall Out Boy & Miranda Lambert 2Health News:Cheap Houston Rodeo Tickets: Ticket Down Slashes Houston Rodeo Tickets for John Legend, Pitbull, Alan Jackson, Tim McGraw, Zac Brown Band, Fall Out Boy & Miranda Lambert 3Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 2Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 2Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 5Health News:Per Wickstrom Offers Guide to Parents for Keeping Youth Sober 2
... disability in the United States, and public school systems ... 166 children is diagnosed with autism, making it more ... ,The Autism Support Services: Education, Research, and Training ... preschool program that uses research-based techniques to address the ...
... the liver are excellent targets for gene therapy using adenoviral ... the differences between cancerous and normal liver cells. The findings ... to the liver, such as metastatic cancers of the colon ... Reid, M.D., Ph.D., of the Moores Cancer Center at University ...
... up the social ladder than bottle-fed children, reveals a large, ... of Disease in Childhood. ,Over 3000 children from ... monitored from birth, as part of the Boyd Orr Study ... ,The study results are based on 1414 people in their ...
... never meet’- health care and mobile technology, it is ... powerful groups - the GSM Association's Development Fund, the ... Accenture Development Partnership, Motorola Inc., MTN South Africa, and ... improve the AIDS/HIV scenario in Africa. ,'The ...
... with lung cancer has won $ 1 million in a lottery. ... an inoperable lung cancer. ,Doctors have given him a ... juncture, he has won this lottery. But the irony that is ... in annual installments over twenty years. ,Schenk is a ...
... for more funds to flow, for those connected with the ... , He was speaking at a meeting where he released ... victims. , The 83-page script was released more ... recovery workers exposed to the dust — a combination of ...
Cached Medicine News:Health News:Autism Expert Creates Innovative Intervention Program 2Health News:Autism Expert Creates Innovative Intervention Program 3Health News:Liver an Excellent Target For Cancer Gene Therapy 2Health News:Liver an Excellent Target For Cancer Gene Therapy 3Health News:Mobile Technology to Meet Healthcare Needs 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: